{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:36:00Z","timestamp":1781649360668,"version":"3.54.5"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Patient Experience"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>Patients with myeloproliferative neoplasm (MPN), including myelofibrosis, polycythemia vera, and essential thrombocythemia, experience a pronounced symptom burden. This study aimed to collect information from physicians and patients in Taiwan to explore their perceptions regarding MPN, treatment goals, and satisfaction with disease management. A cross-sectional, online survey was conducted among patients and physicians from September 2018 to November 2018 in Taiwan as a subset of the expansion of the Landmark survey. Overall, 50 patients with MPN and 30 physicians participated in this study. The symptom burden was low, with the mean number of symptoms experienced being 1.8. The most frequent symptom per physicians\u2019 perception was fatigue, whereas it is not the most common symptom from MPN patients\u2019 perspective. Blood count was the key indicator to determine treatment success from patients\u2019 view, whereas presence of a new symptom was the key indicator from physicians\u2019 perspective. Concordant with previous studies, our study revealed a lack of alignment between physician and patient perceptions relating to treatment goals and disease management. Nevertheless, the physical, emotional, work\/activities and financial impacts on patients were minimal in Taiwan.<\/jats:p>","DOI":"10.1177\/23743735211059053","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T11:53:56Z","timestamp":1637668436000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["A Cross-sectional Study of Patients and Physicians on the Impact of Myeloproliferative Neoplasms on Patient Health: The Landmark Survey From Taiwan"],"prefix":"10.1177","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1016-8125","authenticated-orcid":false,"given":"Cheng-Shyong","family":"Chang","sequence":"first","affiliation":[{"name":"Chang Bing Show Chwan Memorial Hospital, Lukang, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Wen","family":"Chen","sequence":"additional","affiliation":[{"name":"Novartis (Taiwan) Co. Ltd, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Ju","family":"Chiang","sequence":"additional","affiliation":[{"name":"Novartis (Taiwan) Co. Ltd, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Chen","family":"Ku","sequence":"additional","affiliation":[{"name":"Novartis (Taiwan) Co. Ltd, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Ming","family":"Lee","sequence":"additional","affiliation":[{"name":"Novartis (Taiwan) Co. Ltd, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"bibr1-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"bibr2-23743735211059053","doi-asserted-by":"publisher","DOI":"10.5045\/br.2014.49.4.211"},{"key":"bibr3-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23690"},{"key":"bibr4-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2015.10.011"},{"key":"bibr5-23743735211059053","unstructured":"https:\/\/www.hpa.gov.tw\/Pages\/List.aspx?nodeid=269. Accessed on December 07, 2020."},{"key":"bibr6-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863"},{"key":"bibr7-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-577635"},{"key":"bibr8-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2208-2"},{"key":"bibr9-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03610-4"},{"key":"bibr10-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4322-9"},{"key":"bibr11-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15839"},{"key":"bibr12-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3082-y"},{"key":"bibr13-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8436"},{"key":"bibr14-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv203"},{"key":"bibr15-23743735211059053","unstructured":"Pharmaessentia Resubmits Application to the US FDA for Ropeginterferon alfa-2b-njft to Treat Polycythemia Vera (PV). News release. PharmaEssentia Corporation. May 14, 2021. Accessed May 21, 2021. https:\/\/bit.ly\/2SkrTI8"},{"key":"bibr16-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30236-4"},{"key":"bibr17-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-234880"},{"key":"bibr18-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.10.025"},{"key":"bibr19-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.283"},{"key":"bibr20-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0077-1"},{"key":"bibr21-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01314-0"},{"key":"bibr22-23743735211059053","unstructured":"Chang C-S, Xiao Z, Morozova EV, Bang S-M, Alzahrani M, Mycock K, et al. Treatment and disease management practices in patients with MPNs in 6 countries: an expansion Of the MPN landmark survey. In: EHA, 2020, p. 4239."},{"key":"bibr23-23743735211059053","unstructured":"Saydam G, Bang SM, Xiao Z, Chang CS, Alzahrani M, Mycock K, et al. Patient-reported physical, emotional and economic impact of myeloproliferative neoplasms in an expansion of the MPN landmark survey. In: EHA, 2020, p. 4192."},{"key":"bibr24-23743735211059053","doi-asserted-by":"crossref","unstructured":"Xiao  Z, Chang C, Morozova E, Bang S, Alzahrani MA, Mycock K, et al. Impact of myeloproliferative neoplasms (MPNs) and perceptions of treatment goals amongst physicians and patients in 6 countries: an expansion of the MPN landmark survey [poster session]. In EHA, 2019, Abstract No. PF681.","DOI":"10.1097\/01.HS9.0000561008.75001.e7"},{"key":"bibr25-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq458"},{"key":"bibr26-23743735211059053","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa038"},{"key":"bibr27-23743735211059053","doi-asserted-by":"publisher","DOI":"10.5737\/23688076284276281"},{"key":"bibr28-23743735211059053","unstructured":"https:\/\/www.nhi.gov.tw\/Resource\/bulletin\/6562_1050063237-2.pdf. accessed on August 19, 2020."}],"container-title":["Journal of Patient Experience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23743735211059053","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23743735211059053","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23743735211059053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:36:54Z","timestamp":1777509414000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23743735211059053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":28,"alternative-id":["10.1177\/23743735211059053"],"URL":"https:\/\/doi.org\/10.1177\/23743735211059053","relation":{},"ISSN":["2374-3735","2374-3743"],"issn-type":[{"value":"2374-3735","type":"print"},{"value":"2374-3743","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"23743735211059053"}}